Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1990 1
2001 1
2004 1
2005 1
2008 1
2011 2
2012 1
2013 1
2014 2
2015 1
2016 3
2017 3
2018 2
2019 3
2020 9
2021 14
2022 14
2023 14
2024 14
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M. Klümper N, et al. Among authors: darr c. Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764. Clin Cancer Res. 2023. PMID: 36534531 Free PMC article.
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M. Klümper N, et al. Among authors: darr c. J Clin Oncol. 2024 Jul 10;42(20):2446-2455. doi: 10.1200/JCO.23.01983. Epub 2024 Apr 24. J Clin Oncol. 2024. PMID: 38657187 Free PMC article.
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool.
Gandaglia G, Barletta F, Robesti D, Scuderi S, Rajwa P, Gomez Rivas J, Ibanez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler W, Marra G, Stabile A, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Sierra JM, Porpiglia F, Picchio M, van den Bergh R, Shariat SF, Montorsi F, Briganti A. Gandaglia G, et al. Among authors: darr c. Eur Urol Oncol. 2023 Dec;6(6):543-552. doi: 10.1016/j.euo.2023.05.003. Epub 2023 Jun 1. Eur Urol Oncol. 2023. PMID: 37270378
Beta radioguided surgery: towards routine implementation?
Collamati F, van Oosterom MN, Hadaschik BA, Fragoso Costa P, Darr C. Collamati F, et al. Among authors: darr c. Q J Nucl Med Mol Imaging. 2021 Sep;65(3):229-243. doi: 10.23736/S1824-4785.21.03358-6. Epub 2021 May 20. Q J Nucl Med Mol Imaging. 2021. PMID: 34014062 Review.
Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
Zschäbitz S, Biernath N, Hilser T, Höllein A, Zengerling F, Cascucelli J, Paffenholz P, Seidl D, Lutz C, Schlack K, Kingreen D, Klümper N, Ivanyi P, von Amsberg G, Heers H, Roghmann F, Tauber RL, Cathomas R, Hofer L, Niegisch G, Klee M, Ehrenberg R, Hassler A, Hadaschik BA, Grünwald V, Darr C. Zschäbitz S, et al. Among authors: darr c. Eur Urol Open Sci. 2023 May 17;53:31-37. doi: 10.1016/j.euros.2023.04.018. eCollection 2023 Jul. Eur Urol Open Sci. 2023. PMID: 37441344 Free PMC article.
PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?
Küper AT, Kersting D, Telli T, Herrmann K, Rominger A, Afshar-Oromieh A, Lopes L, Karkampouna S, Shi K, Kim M, Hadaschik B, Darr C, Umutlu L, Fendler WP, Seifert R. Küper AT, et al. Among authors: darr c. Theranostics. 2024 Jun 11;14(9):3623-3633. doi: 10.7150/thno.96738. eCollection 2024. Theranostics. 2024. PMID: 38948055 Free PMC article.
Treatment of advanced or metastatic Urothelial Cancer.
Hilser T, Darr C, Bedke J, Ivanyi P, Klümper N, Eckstein M, Schlack K, Grünwald V. Hilser T, et al. Among authors: darr c. Oncol Res Treat. 2025 Mar 26:1-12. doi: 10.1159/000545514. Online ahead of print. Oncol Res Treat. 2025. PMID: 40139170 Review.
Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.
Hilser T, Darr C, Niegisch G, Schnabel MJ, Foller S, Häuser L, Zschäbitz S, Lewerich J, Ivanyi P, Schlack K, Paffenholz P, Daetwyler E, Niedersüß-Beke D, Grünwald V. Hilser T, et al. Among authors: darr c. Cancers (Basel). 2024 Aug 28;16(17):2998. doi: 10.3390/cancers16172998. Cancers (Basel). 2024. PMID: 39272856 Free PMC article.
78 results